Targeting the tumour vasculature: insights from physiological angiogenesis
By Alicia S. Chung, John Lee, N. Ferrara. Nature Reviews. Cancer, 2010
752 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/3d6ddf274cce81a29529cb20c2f34db468f0d8d6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Psychiatry and Mental health
Citations in the corpus
- VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “It is conceivable that such plasticity may be mediated at least in part by the dynamic nature of the microenvironment (Chung et al., 2010).”
- Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. (2011, background): “Among the signaling molecules that regulate the tumor vasculature are members of the vascular-endothelial growth factor (VEGF) pathway, some of which represent validated targets of antiangiogenic therapies (Chung et al., 2010; Kerbel, 2008).”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Indeed, it has been postulated that such plasticity may be mediated by the dynamic nature of the tumour micro-environment 171 .”
- The interaction of anticancer therapies with tumor-associated macrophages (2015, background): “TAMs have proangiogenic activity, and macrophage infiltration in tumors is generally associated with high vascular density (Coffelt et al., 2010).”
- Tumor angiogenesis: molecular pathways and therapeutic targets (2011, background): “Several antiangiogenic therapies are currently approved by the FDA for cancer, including the humanized antibody Avastin (bevacizumab), which targets VEGF-A, the tyrosine kinase inhibitor sorafenib, which targets Raf and VEGF and PDGF receptors, and the tyrosine kinase inhibitor sunitinib, which targ”
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases (2011, background): “VEGF is a key angiogenic factor that stimulates endothelial cell growth, migration, permeability, lumen formation and surviva”